Study Details
Testing the Drug Brelovitug for Adults with Chronic Hepatitis Delta Infection
(IRB#: IRB_00195217)
Chronic (long-term) hepatitis delta virus (HDV) infection, which is the cause of chronic hepatitis D (CHD), leads to severe liver damage. This study will test a drug called brelovitug, also known as BJT-778. The study wants to see if the drug will help people with the disease and is safe. People in the study will receive brelovitug for about 22 months. The study drug is given as an injection under the skin. Being in the study requires attending 26 in-person visits at the study clinic between 2.9 and 3.2 years. Medical tests will be done during the study to track the health of participants. People are paid for study participation.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 18 years and older
- Diagnosis of HDV infection defined as positive for anti-HDV antibody test or HDV RNA at least 6 months before participation
- Willing to take the medication tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), or entecavir (ETV) at baseline, and remain on a stable dose during the study
- Childbearing ages must use specific birth control during study participation
- Able to attend in person at the study clinic
Exclusion Criteria
- Pregnant or breastfeeding
- Current or history of difficulty with blood collection
- Current or history of solid organ or bone marrow transplantation
- Current or history of cardiac (heart) disease
- Specific cancer diagnosed or treated within 5 years of participation
Will I be paid for my time?
Yes
IRB#: IRB_00195217
PI: Juan Gallegos-Orozco
Department: GASTROENTEROLOGY
Approval Date: 2025-12-18 07:00:00
Specialties: Gastroenterology
I am Interested